

Rec'd PCT/ 01 AUG 2005

(19) World Intellectual Property Organization International Bureau



10/544093

(43) International Publication Date
19 August 2004 (19.08.2004)

PCT

(10) International Publication Number
WO 2004/069182 A3

- (51) International Patent Classification⁷: C12N 15/85, 15/86, A61K 39/00, 39/395, C07K 5/00
- (21) International Application Number: PCT/US2004/002856
- (22) International Filing Date: 31 January 2004 (31.01.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/444,150 1 February 2003 (01.02.2003) US
- (71) Applicants (for all designated States except US): NEURALAB LIMITED; 102 St. James Court, FL 04 Flatts, Smiths (BM). WYETH [US/US]; 5 Giralta Farms, Madison, NJ 07940 (US).
- (71) Applicant and
- (72) Inventor (for US only): BARD, Frederique [US/US]; 1111 Park Pacifica Avenue, Pacifica, CA 94044 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): YEDNOCK, Ted [US/US]; 184 Arroyo Road, Forest Knolls, CA 94933 (US). VASQUEZ, Nicki [US/US]; 310 Sanchez Street, San Francisco, CA 94114 (US). SEUBERT, Peter, A. [US/US]; 222 Northwood Drive, South San Francisco, CA 94080 (US).
- (74) Agents: CELLI, Rosemarie et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
3 March 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/069182 A3

(54) Title: ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO SOLUBLE A-BETA

(57) Abstract: The invention provides methods useful for effecting prophylaxis or treatment of Alzheimer's disease. Such methods entail administering A-beta fragments from a central or C-terminal regions of A-beta. Such fragments can induce a polyclonal mixture of antibodies that specifically bind to soluble A-beta without binding to plaques. The antibodies can inhibit formation of amyloid deposits of A-beta in the brain of a patient from soluble A β thus preventing or treating the disease. Fragment A-beta 15-24 and subfragments of 5-10 contiguous amino acids thereof are preferred immunogens due to their capacity to generate a high titer of antibodies.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/02856

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/85, 15/86; A61K 39/00, 39/395; C07K 5/00
US CL : 530/300,350.387.3; 424/130.1,178.1,184.1; 435/325

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/300,350.387.3; 424/130.1,178.1,184.1; 435/325

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SOLOMON, B. Immunological Approaches as Therapy for Alzheimer's Disease. Vaccines & Antibodies December 2002, Vol.2, No. 8, pages 907-017, entire document.	1-102
A	BARD, F. ET AL. Epitope and isotype specificities of antibodies to b-amyloid peptide for protection against Alzheimer's disease-like neuropathology. PNAS 18 February 2003, Vol. 100, No.4, pages 2023-2028, entire document.	1-102
A	LEVERONE, J.F. ET AL. Ab1-15 is less immunogenic than Ab1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting". Vaccine 16 May 2003, Vol. 21, No. 17-18, pages 2197-2206, entire document.	1-102
A	HOLTMAN D.M. ET AL. Ab immunization and anti-Ab antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Advanced Drug Delivery Reviews 7 December 2002, Vol. 54, No. 12, pages 1603-1613, entire document.	1-102
A	SIGURDSSON, E.M. A safer vaccine for Alzheimer's disease? Neurobiology of Aging November/December 2002, Vol. 23, No. 6, pages 1001-1008, entire document.	1-102



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier application or patent published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

15 November 2004 (15.11.2004)

Date of mailing of the international search report

14 DEC 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Christopher J Nichols, Ph.D.

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

<p>International application No. PCT/US04/02856</p>

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/0162129 A1 (LANNEFLT, L. ET AL.) 31 October 2002 (31.10.2002), especially paragraph 0017, 0020, 0032, 0035-0041, page 8.	1, 4-6, 8, 14, 17, 27, 28, 48, 51-53, 55, 61, 64, 74, 75, 96, 99-102
X	US 2002/0094335 A1 (CHALIFOUR, R. ET AL.) 18 July 2002 (18.07.2002), paragraph 0020-0024, 0079-0112, pages 18-20.	1, 4-6, 8, 14, 17, 27, 28, 48, 51-53, 55, 61, 64, 74, 75, 96, 99-102
X	SCHENK, D. ET AL. Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 8 July 1999, Vol. 400, No. 6740, pages 173-177, especially Figures 1-6.	1, 4-6, 8, 48, 51-53, 55, 57-58, 96, 99-102
X	SIGURDSSON, E.M. ET AL. Immunization with a Nontoxic/Nonfibrillar Amyloid- β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice. American Journal of Pathology August 2001, Vol. 159, No. 2, pages 439-447, especially Figure 3.	1, 4-6, 8, 48, 51-53, 55, 57-58, 96, 99-102
X	LEMERÉ, C.A. ET AL. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiology of Aging November/December 2002, Vol. 23, No. 6, pages 991-1000, especially Tables 1-2, Figures 1-3.	1, 4-6, 8, 48, 51-53, 55, 57-58, 96, 99-102

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/02856

Continuation of B. FIELDS SEARCHED Item 3:
WEST (USPT, PGPUBS, JPO, EPO, DERWENT) MEDLINE (PUBMED) STN (BIOSCIENCE)
abeta, beta-amyloid, Alzheimers disease, vaccine, immunogenic fragment, antibody, antigen, epitope